Effects of Cholinergic Drugs and Cognitive Training on Dementia

A study was performed on patients with Alzheimer’s disease (AD) in order to evaluate the efficacy of a combined treatment (donepezil plus cognitive training) in both cognitive processes and affective states. Eighty-six subjects, 25 men and 61 women, with an average age of 75.58 years, were studied. Almost all the subjects had a basic educational level. Donezepil was administered at a dose of 10 mg daily along with cognitive treatment involving images of everyday life and reminiscent music; the sessions took place on Monday to Friday and lasted three quarters of an hour. The study lasted 12 months. Subjects underwent test-retest with the following tests: Mini-Mental State Examination (MMSE), the cognitive subscale of the Alzheimer’s Disease Assessment Scale (ADAS-cog); the Geriatric Depression Scale (GDS) and the overall deterioration scale (FAST). The results showed that subjects receiving the combined treatment had a better response than those who did not receive any cognitive training. These subjects’ MMSE score decreased by 3.24 on average. The affective symptomatology of those receiving only drug treatment improved whereas the cognitive processes did not.

[1]  T. Burt.  Donepezil and related cholinesterase inhibitors as mood and behavioral controlling agents , 2000, Current psychiatry reports.

[2]  N. Foldi,et al.  The effect of attentional dysfunction in Alzheimer's disease: theoretical and practical implications. , 2002, Seminars in speech and language.

[3]  S. Folstein,et al.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.

[4]  Alan B. Stevens,et al.  Memory Interventions for Persons with Dementia , 1996 .

[5]  B. Reisberg,et al.  Functional Staging of Dementia of the Alzheimer Type , 1984 .

[6]  S. Fay,et al.  Goal setting and attainment in Alzheimer’s disease patients treated with donepezil , 2002, Journal of neurology, neurosurgery, and psychiatry.

[7]  J. Brandt,et al.  Long-term retention of implicit learning in Huntington's disease , 1991, Neuropsychologia.

[8]  G. Mckhann.  New neurons for aging brains , 2002, Annals of neurology.

[9]  J. Cummings,et al.  Effect of Tacrine on Behavioral Symptoms in Alzheimer's Disease: An Open-Label Study , 1996, Journal of geriatric psychiatry and neurology.

[10]  B. Wilson,et al.  The development of group memory therapy , 1992 .

[11]  Peter W Thomas,et al.  A randomized controlled trial of the effects of multi-sensory stimulation (MSS) for people with dementia. , 2001, The British journal of clinical psychology.

[12]  L. Frölich,et al.  Der Einfluss eines alltagsbezogenen kognitiven Trainings auf die Aufmerksamkeits- und Gedächtnisleistung von Personen mit Demenz , 2002, Zeitschrift für Gerontologie und Geriatrie.

[13]  R. N. Davis,et al.  Cognitive Intervention in Alzheimer Disease: A Randomized Placebo-Controlled Study , 2001, Alzheimer disease and associated disorders.

[14]  G. Kempermann,et al.  Neuroplasticity in old age: Sustained fivefold induction of hippocampal neurogenesis by long‐term environmental enrichment , 2002, Annals of neurology.

[15]  R. Mohs,et al.  A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients , 2001, Neurology.

[16]  D. Schacter,et al.  Access to consciousness: Dissociations between implicit and explicit knowledge , 1986 .

[17]  P. Maki.  Is implicit memory preserved in Alzheimer's disease? Implications for theories of implicit memory. , 1995 .

[18]  C. Sadowsky,et al.  Effect of tacrine on language, praxis, and noncognitive behavioral problems in Alzheimer disease. , 1997, Archives of neurology.

[19]  J. Brandt,et al.  Memory disorders in the dementias. , 1995 .

[20]  T. Elbert,et al.  New treatments in neurorehabiliation founded on basic research , 2002, Nature Reviews Neuroscience.

[21]  M. Weiner,et al.  Effects of donepezil on emotional/behavioral symptoms in Alzheimer's disease patients. , 2000, The Journal of clinical psychiatry.

[22]  M. Nissen,et al.  Implicit learning in patients with probable Alzheimer's disease , 1987, Neurology.

[23]  Paolo Vitali,et al.  Effects of long-term Donepezil therapy on rCBF of Alzheimer's patients , 2002, Clinical Neurophysiology.

[24]  P. Vitali,et al.  Quantitative EEG Changes in Alzheimer Patients during Long-Term Donepezil Therapy , 2002, Neuropsychobiology.

[25]  J. Liepert,et al.  Treatment-induced cortical reorganization after stroke in humans. , 2000, Stroke.

[26]  Dirk Deleu,et al.  A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. , 2001, Neurology.

[27]  B. Winblad,et al.  A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD , 2001, Neurology.

[28]  V. Leirer,et al.  Development and validation of a geriatric depression screening scale: a preliminary report. , 1982, Journal of psychiatric research.

[29]  K. Davis,et al.  A new rating scale for Alzheimer's disease. , 1984, The American journal of psychiatry.

[30]  D. Giles,et al.  The effects of an orally administered cholinergic agonist on REM sleep in major depression , 2002, Biological Psychiatry.

[31]  B. Gulanski,et al.  Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease , 1998, Neurology.

[32]  Elisabetta Farina,et al.  Comparing two programs of cognitive training in Alzheimer's disease: a pilot study , 2002, Acta neurologica Scandinavica.